RBC starts Schott Pharma with 'sector perform', citing uncertain earnings momentum

SCHOTT Pharma AG & Co KgaA

03/12/2025 09:53

** RBC starts Schott Pharma 1SXP.DE with "sector perform", saying more clarity is needed from the German pharmaceutical industry supplier's outlook amid market uncertainties

** Broker says it waits for full-year 2025 results and new guidance to reassess the investment case, looking for how quickly and to what level GLP-1 contracts can ramp

** "Although SCHOTT Pharma's exposure to biologic and GLP-1 drugs is attractive, its exposure to mRNA has led to downgrades and multiple contraction," RBC says

** Stock has fallen 25% so far this year

** Out of 13 analysts that cover Schott Pharma, 11 rate the stock "strong buy" or "buy,"​ one rates it "hold" and one "sell" - LSEG data

 (Reporting by Amir Orusov)

 ((Amir.orusov@thomsonreuters.com))